Medivir AB (MVIRb.F) Announces Data From Two Phase 3 Studies With Simeprevir in Hepatitis C Subpopulations – HCV/HIV Co-Infected and Genotype 4 Infected Patients
10/18/2013 9:19:24 AM
Stockholm, Sweden — Medivir AB (OMX: MVIR) today announced preliminary data from
two phase III studies conducted by Janssen R&D Ireland evaluating simeprevir in
genotype 4 chronic hepatitis C in adult patients with compensated liver disease,
and in genotype 1 hepatitis C and HIV-1 co-infected adult patients. The data
were presented today at the ongoing European AIDS Conference (EACS), October 16
-19 in Brussels.
Help employers find you! Check out all the jobs and post your resume.
comments powered by